11-01 :: December 2010 / January 2011
nanotimes
Companies Facts
expected, initially, to have the capacity to produ- ce around 25kg of cadmium-free quantum dots (CFQD™) annually.
Commercial-scale batches of high quality red CFQD™ have been successfully manufactured during commissioning. Nanoco is now trialling batches for a specific customer application and expects to be able to deliver 1kg of red CFQD™ to the customer within the next few months. Once validated by the custo- mer, this will, subject to the Company’s satisfaction of certain other contractual terms and conditions, trigger a $2m milestone payment. The Company also anticipates shipping 1kg of green CFQD™ in mid 2011, subject to similar terms and conditions.
Furthermore, Nanoco Group announced the comple- tion of a total of 16,700,000 new ordinary shares in the capital of Nanoco. The shares have been placed with institutions at a price of 89 pence per Placing Share. Based on the Placing Price, the gross proceeds of the Placing will be approximately £15 million ($24 million).
http://www.nanocogroup.com/
T
he German manufacturer of high-precision optical 3D surface analysis tools NanoFocus AG
(Frankfurt: N2F) starts the product development of a new sensor generation with a major contract from the medical technology industry. The optical sensors in the high end segment will become part of a new product family implementing most recent, state-of- the-art technology.
The order is one milestone of a long-term roadmap with high revenue potential for NanoFocus. The bulk order for the medical sensor provides alongside the
recent capital increase a stable foundation for finan- cing further product development and other projects within this area.
“This is a big step towards series production,” says Jürgen Valentin, Managing Board Technology of NanoFocus AG.
http://www.nanofocus.info
N
anogate AG (ISIN DE000A0JKHC9), Germany, has initiated a strategic partnership with Kapy-
fract AG, a major player in Europe’s tunnel fireproo- fing industry. The objective of the partnership is to internationally market and implement innovative coating solutions for traffic tunnels based on Nano- gate-Technologie®
33
. Together, the two companies will
tap the significant market potential available Euro- pean-wide and offer customers a one-stop shop for premium-quality products and services for coating concrete. In recent months, with this in mind, Nano- gate has considerably ramped up its product experti- se and given Kapyfract access to this know-how. The first joint systems are now available by the name of KapyCoat E+.
http://www.nanogate.de
N
anoLogix (PINK OTC Markets: NNLX), an innovator in the accelerated detection and
identification of microorganisms, announced the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the Uni- versity of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publica- tion of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95